Tag: CytoReason

[CytoReason in The Times of Israel] Swiss pharma firm Ferring, Israel’s CytoReason join to battle bowel disease

CytoReason, an Israeli startup that uses artificial intelligence to build digital models of the human immune system and diseases to speed up drug development, said Wednesday it will collaborate with Ferring Pharmaceuticals, a Swiss multinational biopharmaceutical company, to find new treatments for patients with inflammatory bowel disease (IBD). Read...

Read More

[CytoReason in PR Newswire] CytoReason Announces Collaboration with Ferring to Identify Novel Therapeutic Targets in Inflammatory Bowel Disease Using AI Technology

TEL AVIV, Israel, May 19, 2021 /PRNewswire/ — CytoReason, an Israeli company developing a computational model of the human body for faster drug discovery and development, today announced a collaboration with Swiss multinational biopharmaceutical company, Ferring Pharmaceuticals, which aims to establish new treatment options for patients with inflammatory bowel disease (IBD). Read...

Read More

Latest from Twitter